183 related articles for article (PubMed ID: 26885001)
1. Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Int J Clin Exp Med; 2015; 8(11):20778-86. PubMed ID: 26885001
[TBL] [Abstract][Full Text] [Related]
2. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
[TBL] [Abstract][Full Text] [Related]
3. Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
Krishnaswamy S; Mohammed AK; Tripathi G; Alokail MS; Al-Daghri NM
BMC Cancer; 2017 Nov; 17(1):738. PubMed ID: 29121914
[TBL] [Abstract][Full Text] [Related]
4. Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines.
Krishnaswamy S; Bukhari I; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Gene; 2018 Dec; 679():335-340. PubMed ID: 30223007
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
6. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells.
Ling Y; Kuang Y; Chen LL; Lao WF; Zhu YR; Wang LQ; Wang D
Oncotarget; 2017 Jun; 8(24):39101-39116. PubMed ID: 28388571
[TBL] [Abstract][Full Text] [Related]
7. RON alternative splicing regulation in primary ovarian cancer.
Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E
Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
[TBL] [Abstract][Full Text] [Related]
9. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant.
Eckerich C; Schulte A; Martens T; Zapf S; Westphal M; Lamszus K
J Neurochem; 2009 May; 109(4):969-80. PubMed ID: 19519771
[TBL] [Abstract][Full Text] [Related]
10. Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy.
Kim J; Koh DI; Lee M; Park YS; Hong SW; Shin JS; Lee MS; Kim MH; Lee JH; Jeong J; Bae S; Hong JK; Jeong HR; Ryu YS; Kim SM; Choi M; Kim H; Ryu H; Hur SC; Park J; Hur DY; Jin DH
Cell Death Differ; 2023 Dec; 30(12):2491-2507. PubMed ID: 37926711
[TBL] [Abstract][Full Text] [Related]
11. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
Lu Y; Yao HP; Wang MH
Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
[TBL] [Abstract][Full Text] [Related]
12. Small interfering RNA targeting of Recepteur d'Origine Nantais induces apoptosis via modulation of nuclear factor-kappaB and Bcl-2 family in gastric cancer cells.
Park JS; Park JH; Lee S; Joo YE; Jung YD
Oncol Rep; 2010 Sep; 24(3):709-14. PubMed ID: 20664977
[TBL] [Abstract][Full Text] [Related]
13. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
Front Oncol; 2019; 9():1377. PubMed ID: 31867280
[TBL] [Abstract][Full Text] [Related]
14. Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer.
Yu H; Yuan J; Xiao C; Qin Y
Int J Mol Med; 2013 May; 31(5):1248-54. PubMed ID: 23483216
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
Chao KL; Tsai IW; Chen C; Herzberg O
PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655
[TBL] [Abstract][Full Text] [Related]
16. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
Wang MH; Yao HP; Zhou YQ
Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
[TBL] [Abstract][Full Text] [Related]
17. Involvement of recepteur d'origine nantais receptor tyrosine kinase in Epstein-Barr virus-associated nasopharyngeal carcinoma and its metastasis.
Chou YC; Chen CL; Yeh TH; Lin SJ; Chen MR; Doong SL; Lu J; Tsai CH
Am J Pathol; 2012 Nov; 181(5):1773-81. PubMed ID: 22974584
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d'Origine Nantais.
Lian S; Park JS; Xia Y; Nguyen TT; Joo YE; Kim KK; Kim HK; Jung YD
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27689991
[TBL] [Abstract][Full Text] [Related]
19. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais.
Chen YQ; Zhou YQ; Fu LH; Wang D; Wang MH
Carcinogenesis; 2002 Nov; 23(11):1811-9. PubMed ID: 12419829
[TBL] [Abstract][Full Text] [Related]
20. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype.
Collesi C; Santoro MM; Gaudino G; Comoglio PM
Mol Cell Biol; 1996 Oct; 16(10):5518-26. PubMed ID: 8816464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]